ClinicalTrials.gg
CompletedNCT01284764SMWUpdated Oct 5, 2011

Efficacy Study of a Low Volume of Water Intake and Mosapride for Endoscopy in Patients With Subtotal Gastrectomy

A Phase 3 interventional study of Mosapride in Foreign Body Left During Endoscopic Examination, sponsored by Inje University. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-10-05.

Sponsored by Inje University · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 521 studies in Stomach Neoplasms with a site in Korea, Republic of — 78 open to participants now, 116 under way, 20 of them phase 3. Stomach Neoplasms · Korea, Republic of.

Planned enrollment
168th of 448
144 · median 95
Started
2011
with 22 others
Phase 3
89 of 521
10 open now
Registered
87th of 521
by date

Among the 521 studies in Stomach Neoplasms with a site in Korea, Republic of, this one is the 168th largest by planned enrollment of the 448 interventional ones that give a count, is one of 23 that started in 2011, is one of 89 in phase 3, and was the 87th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

78 of the 521 studies in Stomach Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 521 studies in Stomach Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A low volume of water intake and mosapride will effectively reduce food residue in remnant stomach for patients who had undergone subtotal gastrectomy due to gastric cancer.

Read the detailed description

We evaluate that a 500mL of water intake and mosapride will effectively reduce food residue in remnant stomach for patients who had undergone subtotal gastrectomy due to gastric cancer. We plan to compare this method with routine midnight fasting method for endoscopy in patients with subtotal gastrectomy.

03

Conditions studied

  • Foreign Body Left During Endoscopic Examination

Browse trials for

Keywords

  • Endoscopy
  • Gastrectomy
  • Stomach neoplasms
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients who had subtotal gastrectomy for gastric cancer

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Lactation
  • History of anastomotic stricture
  • Recurrent advanced gastric cancer
  • Poor general condition( > 2 )
  • Other disseminated
  • Significant renal failure or congestive heart failure (CHF)
  • Liver failure
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
144 participants (estimated)

Study arms

  • No intervention
    midnight fasting

    The patients in this group will have midnight fasting the day before endoscopic examination

  • Active comparator
    Mosapride, low volume of water

    The patients in this group will take mosapride and a 500mL water at evening of the day before endoscopic examination.

    Drug: Mosapride

Interventions

  • Mosapride 10mg, one dosage, once evening of the day before the endoscopy

    Also known as: Gasmotin

06

What researchers measure

Primary outcomes

  1. Degrees of food residue using endoscopic scoring system

    We plan to evaluate how much a low volume of water and mosapride, compared with routine fasting, reduse food residue in gastric remnant for endoscopy.

    Time frame: six months

Secondary outcomes

  1. Tolerability of a low volume of water and mosapride

    We plan to evaluate tolerability of a low volume of water and mosapride compared with routine fasting for endoscopy preparation in patients with subtotal gastrectomy

    Time frame: six months

07

Study locations

1 site
  • Haeundae Paik Hospital, Inje University School of Medicine
    Busan, 612-030, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Jul 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2011
First posted
Jan 27, 2011
Start
Jan 2011
Primary completionActual
Jul 2011
CompletionActual
Sep 2011
Last update
Oct 5, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01284764
Lead sponsor
Inje University
Responsible party
Eun Hee Seo (fellow, Inje University) — Principal investigator
First posted
Jan 27, 2011
Start date
Jan 2011
Primary completion
Jul 2011
Completion
Sep 2011
Last update
Oct 5, 2011

Study contacts

Eun Hee Seo, M.D.
principal investigator · Haeundae Paik Hospital
Tae Oh Kim, Ph.D.
study director · Haeundae Paik Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mosapride

Start the discussion